Vertex Pharma (VRTX): Nivalis Setback Positive For Orkambi - BMO
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
BMO Capital analyst, Do Kim, reiterated his Market Perform rating on Vertex (NASDAQ: VRTX) price after the Phase II failure of Nivalis's cavosonstat should have a minimal direct impact on the company considering his view that cavosonstat is an add-on therapy to Vertex's drugs and not a direct competitor.
However, he also sees the trial miss as an incremental positive, as it highlights the difficulty of CF drug development and emphasizes the significant lead Vertex has over competitors. No change to the price target of $88.
Shares of Vertex closed at $86.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Google's (GOOGL) PT Raised to $1,000 at BMO Capital
- Polaris Industries (PII) PT Raised to $85 at Stifel Ahead of 4Q Report
- JPMorgan Downgrades Endo International plc (ENDP) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!